Takeda: Top Line Beats Consensus, Steady Pipeline Progress and Further Upside
Takeda has not revised full-year forecast, however, we think a large beat is incoming. There is further upside as it pushes forward with its...
China Healthcare Weekly (Jan.27) - Surgical Robots New Policy, COVID-19 Update, Policy Vacuum Period
New policy released to support development of surgical robot. COVID-19 is no longer an excuse for company's poor performance. It's a good time to...
Hutchmed China Ltd (13.HK/HCM.US) - The $1.13B Eye-Catching Deal with Takeda and the New Outlook
HUTCHMED/Takeda $1.13 billion license agreement is very worthy of learning.Together with savolitinib's inclusion in new NRDL,2023 performance...
Takeda Strengthens Oncology Portfolio with HUTCHMED’s Fruquintinib Acquisition
Takeda's exclusive licensing agreement with HUTCHMED for further development and commercialisation of Fruquintinib should help its oncology biz...
Smartkarma Originals